Compare HZO & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | SANA |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.1M | 793.1M |
| IPO Year | 1998 | 2021 |
| Metric | HZO | SANA |
|---|---|---|
| Price | $52.32 | $2.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $30.00 | $7.80 |
| AVG Volume (30 Days) | 723.6K | ★ 3.4M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,309,288,000.00 | N/A |
| Revenue This Year | $3.67 | N/A |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $249.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.42 | $2.61 |
| 52 Week High | $52.54 | $6.55 |
| Indicator | HZO | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 75.60 | 36.57 |
| Support Level | $52.08 | $2.64 |
| Resistance Level | $52.40 | $3.41 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | -0.40 | -0.03 |
| Stochastic Oscillator | 52.63 | 9.00 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.